Loading...
01/09 23:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
AbbVie's earnings call reveals strong financial performance and optimistic guidance, with raised EPS and revenue expectations. The Q&A session highlights confidence in key products like Skyrizi and Rinvoq, despite minor biosimilar impacts. Neuroscience and pipeline growth are promising, while aesthetics face challenges. Management's strategic focus on pipeline development and business expansion supports positive sentiment. Overall, the company's robust outlook and strategic initiatives indicate a likely positive stock price movement over the next two weeks.
Adjusted Earnings Per Share (EPS) $2.97, which is $0.11 above the guidance midpoint. The increase was driven by strong financial performance across various segments.
Total Net Revenues $15.4 billion, reflecting growth of 6.5% on an operational basis. This was $400 million ahead of expectations, driven by strong sales growth in the ex-HUMIRA platform, neuroscience, and other key areas.
Skyrizi Global Sales $4.4 billion, up 61.8% on an operational basis. Growth was driven by strong performance in psoriatic disease and IBD, with significant market leadership in psoriasis and Crohn's disease.
Rinvoq Global Sales $2 billion, up 41.2% on an operational basis. Growth was attributed to strong uptake in IBD and other indications, including a successful launch in giant cell arteritis.
HUMIRA Global Sales $1.1 billion, down 58.2% on an operational basis. The decline was due to biosimilar competition and reduced access in the U.S.
Oncology Total Revenues Nearly $1.7 billion. IMBRUVICA sales were $754 million, down 9.5% due to competitive dynamics in CLL, while Venclexta revenues were $691 million, up 8.3% due to strong demand in CLL.
Aesthetics Global Sales Nearly $1.3 billion, down 8% on an operational basis. The decline was attributed to economic challenges and lower consumer sentiment impacting the aesthetics market.
Neuroscience Total Revenues Approximately $2.7 billion, up 24% on an operational basis. Growth was driven by double-digit increases in Vraylar, BOTOX Therapeutic, Ubrelvy, and QULIPTA sales.
Skyrizi and Rinvoq: Sales growth of 22% from the ex-HUMIRA platform, with Skyrizi and Rinvoq on pace to deliver more than $25 billion in combined sales this year, exceeding expectations.
EMRELIS and Rinvoq: Recent approvals for non-squamous non-small cell lung cancer and GCA, respectively. Rinvoq also showed promising Phase III results in alopecia areata.
TrenibotE: Regulatory submission for a first-in-class short-acting toxin in aesthetics.
QULIPTA: Positive results from the head-to-head TEMPLE study for migraine prevention, showing fewer adverse events and better efficacy compared to topiramate.
Immunology: Skyrizi and Rinvoq capturing significant market share in Crohn's disease and ulcerative colitis, with Skyrizi achieving global leadership in psoriatic disease.
Oncology: Launch of EMRELIS for non-squamous non-small cell lung cancer and strong performance of Venclexta in CLL.
Neuroscience: Strong growth in Vraylar, Ubrelvy, and QULIPTA, with VYALEV showing excellent uptake in Parkinson's disease.
Revenue and Earnings: Adjusted earnings per share of $2.97, exceeding guidance by $0.11. Total net revenues of $15.4 billion, $400 million above expectations.
Pipeline Development: Executed over 30 business development transactions since last year, including acquisitions and collaborations to strengthen the pipeline.
Cost Management: Adjusted gross margin of 84.4% and adjusted operating margin ratio of 44.3%.
Acquisitions and Collaborations: Acquired Capstan Therapeutics for in vivo CAR-T platform and announced collaborations with ADARx and IGI Therapeutics for innovative therapies.
Pipeline Expansion: Focus on therapies and technologies to elevate the standard of care, including early-stage programs for long-term growth.
Biosimilar Competition for HUMIRA: HUMIRA's global sales have decreased by 58.2% due to biosimilar competition, and access in the U.S. is expected to decline further as more plans adopt exclusionary formularies for existing patients.
Economic Challenges in Aesthetics Market: Economic challenges and lower consumer sentiment have negatively impacted the aesthetics market, leading to an 8% decline in global sales for aesthetics products like BOTOX Cosmetic and JUVÉDERM.
Competitive Dynamics in Oncology: IMBRUVICA's global sales have declined by 9.5% due to competitive pressures in the chronic lymphocytic leukemia (CLL) market, despite higher persistency rates for existing patients.
Regulatory and Clinical Risks: Several pipeline products, including Rinvoq for alopecia areata and vitiligo, are awaiting regulatory approvals or clinical trial results, which could impact future growth if outcomes are unfavorable.
Supply Chain and Market Access Risks: The company faces risks related to market access and supply chain disruptions, particularly in the context of launching new products and maintaining existing ones.
Economic Sensitivity of Neuroscience Portfolio: While neuroscience products have shown strong growth, their performance could be sensitive to economic conditions and healthcare budget constraints.
Revenue Guidance: AbbVie raised its full-year revenue guidance to $60.5 billion, an increase of $800 million. This marks a $1.5 billion increase in revenue guidance since the start of the year.
Earnings Per Share (EPS) Guidance: The company raised its full-year adjusted EPS guidance to a range of $11.88 to $12.08, reflecting an increase of $0.21.
Immunology Revenue Projections: Skyrizi global revenues are now expected to reach $17.1 billion, an increase of $600 million, driven by share gains in psoriasis and IBD. U.S. HUMIRA revenues are projected at $3 billion, a decrease of $500 million due to biosimilar competition.
Neuroscience Revenue Projections: Global sales for neuroscience are now expected to reach $10.5 billion, an increase of $300 million. This includes a $100 million increase for VYALEV and $200 million split across Vraylar, BOTOX Therapeutic, and the oral CGRP portfolio.
Oncology Revenue Projections: Imbruvica global revenues are projected at $2.9 billion, an increase of $100 million, while Venclexta global sales are expected to reach $2.8 billion, also an increase of $100 million.
Aesthetics Market Outlook: Economic challenges and lower consumer sentiment continue to impact the aesthetics market. However, AbbVie remains optimistic about long-term growth, supported by new product launches like TrenibotE, expected to commercialize next year.
Pipeline and R&D Outlook: AbbVie highlighted progress in its R&D pipeline, including the planned acquisition of Capstan Therapeutics for in vivo CAR-T technology and promising Phase III results for Rinvoq in alopecia areata. Regulatory submissions for Rinvoq in alopecia areata are expected later this year.
Parkinson's Disease Portfolio: AbbVie anticipates its Parkinson's disease portfolio, including VYALEV, Duodopa, and tavapadon, to collectively become a multibillion-dollar opportunity over the long term.
Migraine Treatment Expansion: Positive results from the TEMPLE study for QULIPTA are expected to support earlier adoption as a first-line treatment for migraine prevention.
The selected topic was not discussed during the call.
AbbVie has raised its revenue and EPS guidance, indicating strong financial performance. Skyrizi and Rinvoq are expected to exceed guidance, and there is optimism in the neuroscience and immunology portfolios. Despite challenges in the aesthetics market and Humira erosion, the company anticipates growth driven by pipeline advancements and strategic acquisitions. The Q&A highlighted strong competitive positioning and market share gains. While some uncertainties remain, the overall sentiment is positive, suggesting a stock price increase in the short term.
AbbVie's earnings call reveals strong financial performance and optimistic guidance, with raised EPS and revenue expectations. The Q&A session highlights confidence in key products like Skyrizi and Rinvoq, despite minor biosimilar impacts. Neuroscience and pipeline growth are promising, while aesthetics face challenges. Management's strategic focus on pipeline development and business expansion supports positive sentiment. Overall, the company's robust outlook and strategic initiatives indicate a likely positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
